glp 1 class drugs GLP-1 Agonists: A Comprehensive Overview The Rise of GLP-1 Medications

Keywords: Atherosclerotic cardiovascular disease, Microvascular disease, Diabetes mellitus, Thrombosis, Chronic kidney disease, GLP-1R agonists Introduction Diabetes mellitus (DM) affects over 422 million individuals globally, with projections indicating a rise to 783 million by 2045, representing 10.5% of the adult population

As of December 2025, GLP-1 RA prescriptions account for more than 7% of all prescriptions

Common adverse reactions included nausea, diarrhea, and vomiting

Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines

Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hfner M, Schmiegel WH

These agents exert beneficial effects on myocardial contractility, vascular tone, endothelial integrity, and platelet aggregation, while also modulating inflammation, oxidative stress, and metabolic homeostasis at the cellular and molecular levels